Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Alprazolam

FDA-approved product (tablet, oral), marketed as Alprazolam, Niravam, Xanax and 1 more.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Alprazolam
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Anxiety
  • Anxiety disorder
  • Generalized anxiety disorder
  • Panic disorder

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Benzodiazepine derivatives
FDA pharmacologic class
Benzodiazepine FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis and MRSA. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA54.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli36.7% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae14.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis63.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Alprazolam in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-9.7 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-8.2 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-7.2 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Alprazolam with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Role of Alprazolam in Management of Post Endodontic Pain After Single Visit Root Canal Treatment. To Compare Mean Pain Score Between Two Group of Participants Undergoing Post Operative Pain Management After Single Visit Root Canal Treatment: NSAIDs Alone and a Combination of NSAIDs and Alprazolam.

    NCT07275710 · start 2026-07-30

    Registered record
    Registry ID
    NCT07275710
    Conditions
    Pain
    Interventions
    Brufen and alprazolam; Brufen
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Recruiting
    Start
    2026-07-30
    Completion
    2027-02-01
    Enrolment
    110

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPain
    InterventionBrufen and alprazolam; Brufen
    PhaseNot applicable
    Registry statusRecruiting

  • An Extension Test of Whether to Use Oral Anti-anxiety Drugs (Alprazolam) When Patients Choose Second Eye Cataract Surgery After Unblinding, and Analyze Their Anxiety, Satisfaction and Pain Satisfaction

    NCT06874452 · start 2025-03-25

    Registered record
    Registry ID
    NCT06874452
    Conditions
    Ophthalmology; Cataract Surgery Anesthesia; Oral Anxiolytic; Satisfaction Survey
    Interventions
    Alprazolam (Xanax); Placebo Tablets
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2025-03-25
    Completion
    2027-12-31
    Enrolment
    250

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOphthalmology; Cataract Surgery Anesthesia; Oral Anxiolytic; Satisfaction Survey
    InterventionAlprazolam (Xanax); Placebo Tablets
    PhasePhase 4
    Registry statusRecruiting

  • Opioid/Benzodiazepine Polydrug Abuse: Aim 3

    NCT05006079 · start 2024-03-13

    Registered record
    Registry ID
    NCT05006079
    Conditions
    Opioid Abuse; Benzodiazepine Abuse; Polysubstance Abuse
    Interventions
    Morphine; Alprazolam; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2024-03-13
    Completion
    2026-12
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOpioid Abuse; Benzodiazepine Abuse; Polysubstance Abuse
    InterventionMorphine; Alprazolam; Placebo
    PhasePhase 2
    Registry statusRecruiting

  • Anxiety and Surgery Satisfaction for Cataract Patient With Different State Anxiety

    NCT06826417 · start 2024-01-02

    Registered record
    Registry ID
    NCT06826417
    Conditions
    Oral Anxiolytic; Phacoemulsification; Cataract Surgery; Satisfaction Survey; State Anxiety
    Interventions
    Xanax; placebo tablets
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Recruiting
    Start
    2024-01-02
    Completion
    2026-12-31
    Enrolment
    400

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOral Anxiolytic; Phacoemulsification; Cataract Surgery; Satisfaction Survey +1 more
    InterventionXanax; placebo tablets
    PhaseNot applicable
    Registry statusRecruiting

  • Efficacy of Hydroxyzine for Patients With Panic Disorder

    NCT05737511 · start 2023-12-30

    Registered record
    Registry ID
    NCT05737511
    Conditions
    Panic Disorder
    Interventions
    Hydroxyzine; Escitalopram Oxalate
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Not yet recruiting
    Start
    2023-12-30
    Completion
    2026-12-30
    Enrolment
    80

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPanic Disorder
    InterventionHydroxyzine; Escitalopram Oxalate
    PhasePhase 4
    Registry statusNot yet recruiting

  • A Relative Bioavailability Study of Staccato Alprazolam Versus Oral Alprazolam in Healthy Study Participants

    NCT05626439 · start 2022-12-28

    Registered record
    Registry ID
    NCT05626439
    Conditions
    Healthy Participants
    Interventions
    Staccato alprazolam; Oral alprazolam
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2022-12-28
    Completion
    2023-02-24
    Enrolment
    21

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Participants
    InterventionStaccato alprazolam; Oral alprazolam
    PhasePhase 1
    Registry statusCompleted

  • A Study to Test the Efficacy and Safety of Staccato Alprazolam in Study Participants 12 Years of Age and Older With Stereotypical Prolonged Seizures

    NCT05077904 · start 2021-12-07

    Registered record
    Registry ID
    NCT05077904
    Conditions
    Stereotypical Prolonged Seizures
    Interventions
    Staccato alprazolam; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2021-12-07
    Completion
    2026-09-30
    Enrolment
    350

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionStereotypical Prolonged Seizures
    InterventionStaccato alprazolam; Placebo
    PhasePhase 3
    Registry statusRecruiting

  • A Study to Assess the Pharmacokinetics (PK) and Safety of Staccato Alprazolam in Adolescent Study Participants With Epilepsy

    NCT04857307 · start 2021-04-28

    Registered record
    Registry ID
    NCT04857307
    Conditions
    Epilepsy
    Interventions
    Alprazolam
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2021-04-28
    Completion
    2022-04-05
    Enrolment
    14

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEpilepsy
    InterventionAlprazolam
    PhasePhase 1
    Registry statusCompleted

  • Study to Assess the Safety, Tolerability, And Pharmacokinetics of Staccato Alprazolam in Healthy Japanese, Chinese, and Caucasian Participants

    NCT04782388 · start 2021-03-04

    Registered record
    Registry ID
    NCT04782388
    Conditions
    Healthy Study Participants
    Interventions
    Alprazolam; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2021-03-04
    Completion
    2021-04-26
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Study Participants
    InterventionAlprazolam; Placebo
    PhasePhase 1
    Registry statusCompleted

  • Licorice Botanical Dietary Supplements - Metabolism and Safety in Women

    NCT03948243 · start 2019-04-01

    Registered record
    Registry ID
    NCT03948243
    Conditions
    Food-drug Interaction
    Interventions
    Licorice; Alprazolam 2 MG; Caffeine 100 MG; Tolbutamide 250 mg; Dextromethorphan 30mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2019-04-01
    Completion
    2022-04-22
    Enrolment
    19

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionFood-drug Interaction
    InterventionLicorice; Alprazolam 2 MG; Caffeine 100 MG; Tolbutamide 250 mg +1 more
    PhasePhase 1
    Registry statusCompleted

  • Preoperative Hypnosis Versus Premedication in Gynecological Surgery

    NCT03327506 · start 2018-11-27

    Registered record
    Registry ID
    NCT03327506
    Conditions
    Gynecologic Disease; Anxiety Disease
    Interventions
    Alprazolam 0.5 mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2018-11-27
    Completion
    2021-12
    Enrolment
    128

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGynecologic Disease; Anxiety Disease
    InterventionAlprazolam 0.5 mg
    PhasePhase 4
    Registry statusUnknown

  • Evaluation of Safety and Diabetes Status Upon Oral Treatment With GABA in Patients With Longstanding Type-1 Diabetes

    NCT03635437 · start 2018-09-05

    Registered record
    Registry ID
    NCT03635437
    Conditions
    Type 1 Diabetes Mellitus
    Interventions
    Gamma-Aminobutyric Acid (GABA); Alprazolam
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2018-09-05
    Completion
    2022-09-27
    Enrolment
    35

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionType 1 Diabetes Mellitus
    InterventionGamma-Aminobutyric Acid (GABA); Alprazolam
    PhasePhase 1 / Phase 2
    Registry statusCompleted

  • Evaluation of the Effects of Cannabidiol (CBD) Compared to Delta-9-Tetrahydrocannabinol (THC) and Alprazolam

    NCT03398083 · start 2017-12-04

    Registered record
    Registry ID
    NCT03398083
    Conditions
    Cannabis Use Disorder
    Interventions
    THC; Alprazolam; Placebo oral capsule; CBD
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2017-12-04
    Completion
    2018-05-30
    Enrolment
    42

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCannabis Use Disorder
    InterventionTHC; Alprazolam; Placebo oral capsule; CBD
    PhasePhase 1
    Registry statusCompleted

  • A Study of the Abuse Potential of Lasmiditan in Participants Who Are Recreational Drug Users

    NCT03286218 · start 2017-09-15

    Registered record
    Registry ID
    NCT03286218
    Conditions
    Recreational Drug Use; Prescription Drug Abuse (Not Dependent)
    Interventions
    Lasmiditan; Alprazolam; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2017-09-15
    Completion
    2017-11-20
    Enrolment
    96

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRecreational Drug Use; Prescription Drug Abuse (Not Dependent)
    InterventionLasmiditan; Alprazolam; Placebo
    PhasePhase 1
    Registry statusCompleted

  • Sedative-Anxiolytic Effects on Simulated Driving Performance

    NCT03297944 · start 2017-09-15

    Registered record
    Registry ID
    NCT03297944
    Conditions
    Psychomotor Impairment
    Interventions
    Alprazolam 2mg (2ALP/PLC); Alprazolam 1mg (1ALP/PLC); Alprazolam 0.5mg (0.5ALP/PLC); Zolpidem 10mg (ZOL/PLC); Placebo (PLC/PLC); Alprazolam 1mg (PLC/ALC)
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2017-09-15
    Completion
    2018-10-25
    Enrolment
    15

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPsychomotor Impairment
    InterventionAlprazolam 2mg (2ALP/PLC); Alprazolam 1mg (1ALP/PLC); Alprazolam 0.5mg (0.5ALP/PLC); Zolpidem 10mg (ZOL/PLC) +2 more
    PhasePhase 4
    Registry statusCompleted